Vectura Group’s (VEC) Overweight Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their overweight rating on shares of Vectura Group (LON:VEC) in a research note issued to investors on Thursday.

A number of other equities analysts also recently commented on the company. Peel Hunt restated a hold rating and set a GBX 160 ($2.17) target price on shares of Vectura Group in a report on Wednesday, January 24th. Numis Securities restated a buy rating and set a GBX 170 ($2.31) target price on shares of Vectura Group in a report on Thursday, January 4th. Shore Capital restated a buy rating on shares of Vectura Group in a report on Thursday, January 4th. Royal Bank of Canada upgraded Vectura Group to a sector performer rating and set a GBX 119 ($1.61) target price for the company in a report on Thursday, December 14th. Finally, Panmure Gordon reiterated a buy rating and issued a GBX 150 ($2.03) price objective on shares of Vectura Group in a report on Thursday, November 9th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Vectura Group has a consensus rating of Buy and a consensus price target of GBX 174 ($2.36).

Vectura Group (VEC) opened at GBX 107.10 ($1.45) on Thursday. Vectura Group has a twelve month low of GBX 86.50 ($1.17) and a twelve month high of GBX 166.97 ($2.26).

ILLEGAL ACTIVITY WARNING: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/29/vectura-groups-vec-overweight-rating-reiterated-at-jpmorgan-chase-co.html.

About Vectura Group

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply